TRACON Pharmaceutical (TCON) Tops Q2 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to TRACON Pharmaceutical (TCON) Tops Q2 EPS by 15c

TRACON Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update

August 5, 2015 4:06 PM EDT

Phase 2 clinical trials of TRC105 suggest activity in angiosarcoma and hepatocellular carcinoma

IND filed for the initiation of clinical trials in wet AMD

Cash balance of $61.2 million at June 30, 2015

SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced its financial results for the second quarter ended June 30, 2015.

Second Quarter 2015 and Recent... More